33924-45-7

Basic information

• Product Name: 2-broMo-1-(broMoMethyl)-4-chlorobenzene
• Synonyms: 2-broMo-1-(broMoMethyl)-4-chlorobenzene;2-BROMO-4-CHLOROBENZYL BROMIDE;2-bromo-1-(bromomethyl)-4-chlorobenzene 97%;Benzene, 2-bromo-1-(bromomethyl)-4-chloro-
• CAS NO: 33924-45-7
• Molecular Formula: C₇H₅Br₂Cl
• Molecular Weight: 284.3756
• EINECS: -0
• Mol File: 33924-45-7.mol

Chemical Properties

• Boiling Point: 138-142 °C(Press: 12 Torr)
• Appearance: /
• Density: 1.933±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-broMo-1-(broMoMethyl)-4-chlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-broMo-1-(broMoMethyl)-4-chlorobenzene(33924-45-7)
• EPA Substance Registry System: 2-broMo-1-(broMoMethyl)-4-chlorobenzene(33924-45-7)

Safety Data

• Hazardous Substances Data: 33924-45-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2-Bromo-1-(bromomethyl)-4-chlorobenzene is used as an intermediate compound for the production of other chemical compounds through chemical reactions. Its unique structure with two bromine atoms and one chlorine atom allows it to participate in various chemical processes, making it a valuable building block in the synthesis of more complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Bromo-1-(bromomethyl)-4-chlorobenzene is used as a starting material for the synthesis of various drug molecules. Its reactivity and structural features enable the creation of new compounds with potential therapeutic applications.
Used in Material Science:
2-Bromo-1-(bromomethyl)-4-chlorobenzene is also used in material science for the development of new materials with specific properties. Its halogenated nature can contribute to the creation of materials with altered electronic, optical, or mechanical properties, depending on the desired application.

Upstream product

• 143888-84-0 (2-bromo-4-chloro-phenyl)methanol 
• 1202889-66-4 2-bromo-4-chloro-1-(dibromomethyl)benzene 
• 5551-11-1 4-Chloro-2-nitrobenzaldehyde 
• 32989-56-3 4-chloro-1-[(2-dimethylamino)ethenyl]-2-nitrobenzene 
• 89-59-8 4-chloro-2-nitrotoluene 
• 84459-33-6 2-bromo-4-chlorobenzaldehyde 
• 106-43-4 para-chlorotoluene 
• 27139-97-5 2-bromo-4-chloro-1-methyl-benzene 

Downstream Products

• 760945-91-3 1-(2-bromo-4-chlorobenzyl)-2-acetylpyrrole 
• 13080-74-5 3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepine 
• 223787-50-6 C₁₄H₈BrCl₂NO₂ 
• 52864-55-8 Ethyl-2-brom-4-chlorphenylacetat 
• 52864-54-7 2-(2-bromo-4-chlorophenyl)acetonitrile 
• 66192-10-7 diethyl (2-bromo-4-chlorobenzyl)methyl-malonate 
• 1438825-38-7 (2-butyl-5-chlorophenyl)dimethylsilane 
• 1438826-96-0 C₁₈H₃₀BClO₂Si 
• 66192-17-4 2-(2-Bromo-4-chloro-benzyl)-malonic acid diethyl ester 
• 223787-50-6 C₁₄H₈BrCl₂NO₂ 
• 874285-02-6 2-(4-chloro-2-methoxyphenyl)ethanamine 

Relevant articles and documents

DIBENZOHETEROCYCLIC COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF

A dibenzoheterocyclic compound wherein band gaps of HOMO and LUMO energy levels of the dibenzoheterocyclic compound are wide, light can be emitted in a deep blue light-emitting region; and the LUMO energy level of the dibenzoheterocyclic compound is low, so the LUMO energy level matches with an electron transport layer for electrons injection and transport. The dibenzoheterocyclic compound has hole transport performance, so as a light-emitting layer material, the dibenzoheterocyclic compound balances the ratio of electrons to holes in a light-emitting layer increasing the combination probability and improving the device light-emitting efficiency. The spatial configuration of the dibenzoheterocyclic compound avoids material stacking molecules, reduces annihilation of excitons, and inhibits efficiency roll-off. The dibenzoheterocyclic compound has thermal stability, so deep blue light can be emitted efficiently and stably. With an organic light-emitting diode and a deep blue light-emitting device with high light-emitting efficiency, low working voltage can be obtained.

Cross-coupling strategy for the synthesis of diazocines

Ethylene bridged azobenzenes are novel, promising molecular switches that are thermodynamically more stable in the (Z) than in the (E) configuration, contrary to the linear azobenzene. However, their previous synthetic routes were often not general, and yields were poorly reproducible, and sometimes very low. Here we present a new synthetic strategy that is both versatile and reliable. Starting from widely available 2-bromobenzyl bromides, the designated molecules can be obtained in three simple steps.

A two-benzo heterocyclic compound and its preparation method and application (by machine translation)

The present invention discloses a two-benzo heterocyclic compound, of formula (I) as shown in the structure. Dibenzofluorene and heterocyclic compounds of the LUMO energy level is low, with the electronic transmission material good matching, favorable to electronic injection and transmission. Dibenzofluorene and heterocyclic compound having good hole transmission performance, as luminescent material in the luminescent layer can balance the proportion of electrons and holes, improve the composite probability, make the device light-emitting efficiency is enhanced. Dibenzofluorene and heterocyclic compounds of space configuration can avoid material molecular stacking, and then prevent the intermolecular energy transfer result in high-energy exciton generation, reduce the exciton annihilation, inhibit efficiency roll-off. At the same time, dibenzo heterocyclic compound having good thermal stability, can achieve high-efficiency stable blue-light. The invention also discloses an organic electroluminescent device, at least one functional layer containing the above-mentioned in-diazepine heterocyclic compound, can be obtained with high blue light emitting efficiency and low operating voltage of blue light device. (by machine translation)

Preparation method of impurity isomer key intermediate of anti-depressive drug

The invention relates to a preparation method of an impurity isomer key intermediate of an anti-depressive drug. The preparation method comprises the following steps: (a) mixing sodium periodate, water and DMF (Dimethylformamide); (b) pouring in ice water, adjusting pH with an alkaline solution, extracting by layers, purifying to obtain a compound 4, and performing column chromatography isolationafter reacting at 120 to 150 DEG C to obtain a compound 5; (c) adding the compound 3 and the compound 5 into 1,2-dimethoxyethane, adding sodium hydride under the condition of ice water bath, heating to 40 to 60 DEG C for reacting for 20 to 40 minutes, and heating and refluxing; (d) mixing the compound 6 with a rhodium carbon catalyst, morpholine, methanol and ethanol, reacting under a hydrogen atmosphere, and performing suction filtration and spin drying on filtrate to obtain a compound 7; (e) mixing the compound 7 with formic acid and sodium formate, and heating to 100 to 120 DEG C for refluxreaction; (f) adding anhydrous K2CO3,Cu powder and CuBr, performing reaction under the protection of insert gas at the temperature of 150 to 180 DEG C to obtain a compound 9; cooling to 30 to 60 DEGC, adding NaOH solution to perform reaction, filtering, and purfying to obtain a compound 10.. By adopting the preparation method, a high-purity impurity isomer of the anti-depressive drug can be obtained for accurate control of impurities.

Preparation method of chloronitrophenyl intermediate serving as impurity isomer of medicine for treating depression

The invention relates to a preparation method of a chloronitrophenyl intermediate serving as an impurity isomer of medicine for treating depression. The method includes the following steps that a, sodium periodate, water and DMF are mixed, then a DMF solution of a compound 2 is added for a reaction, and after the reaction, a filtrate is taken and purified to obtain a compound 3; b, 2-bromo-4-chlorotoluene, N-bromosuccinimide, dibenzoyl peroxide and carbon tetrachloride are mixed, stirred, heated to 80-100 DEG C for a reaction and then poured into ice water, the pH is adjusted with lye, and layered extraction and purification are conducted to obtain a compound 4; c, the compound 3 and a compound 5 are added into glycol dimethyl ether, sodium hydride is added under the condition of an ice water bath, the temperature is raised to 40-60 DEG C for a reaction for 20-40 minutes, then the temperature is raised for reflux, after the reaction is completed, water and ethyl acetate are added in avolume ratio of 1:1, and solid is precipitated, subjected to suction filtration and dried to obtain a compound 6. In this way, the nitrophenyl intermediate with high purity can be obtained to be usedfor subsequent preparation of the high-purity and high-yield impurity isomer of medicine for treating depression.

A depression drug impurity of preparing method (by machine translation)

The invention relates to a depression drug impurity of preparing method, it comprises the following steps: (a) the high sodium iodate, water and mixed DMF; (b) is poured into ice water, adjusting pH with alkali and layered extraction, purification to obtain compound 4; in the 120 - 150 °C reaction after column chromatography separation to obtain compound 5; (c) the compound 3 and said compound 5 by adding ethylene glycol dimethyl ether, in the ice water bath under the conditions of the adding sodium hydride to, heating up to 40 - 60 °C reaction 20 - 40 minutes, further heating up to reflux; (d) the compound 6 with the [...] catalyst, morpholine, methanol and ethanol are mixed, the reaction is carried out in a hydrogen atmosphere, filtered [...] filtrate to obtain compound 7; (e) the compound 7 with formic acid, a sodium mixed, heated to 100 - 120 °C refluxing reaction; (g) the compound 10 in toluene soluble, in an inert gas atmosphere by adding sodium hydride, temperature reaction. This can obtain the high purity of the depression drug impurity isomer, for impurity accurate control. (by machine translation)

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are chemical entities which are compounds of formula (I); or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra', Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Palladium(0)-catalyzed arylative dearomatization of phenols

The palladium-catalyzed arylative dearomatization of phenols to yield spirocyclohexadienone products in good to excellent yields has been developed. Preliminary results demonstrate that the formation of the spirocyclic all-carbon quaternary center can be accomplished with high levels of enantiocontrol (up to 91% ee).

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.